A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
Clinical trial NCT02392234 · COMPLETED
Trial details
- NCT number
- NCT02392234
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2017-02-01
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.